Case series: New-onset freezing of gait in combined use of deep brain stimulation and Levodopa

Mehri Salari1 | Zahra Aminzade2 | Reza Jalili khoshnood1 | Sepand Tehrani Fateh2

1Functional Neurosurgery Research Center, Shohada Tajrish Comprehensive Neurosurgical Center of Excellence, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Correspondence
Sepand Tehrani Fateh, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Email: Sepand.tf@gmail.com

Funding information
None of the authors have received any funding of any kind for either this project or other projects

1 | INTRODUCTION

The effect of DBS on occurrence or improvement of freezing of gait (FoG) in the course of Parkinson’s Disease (PD) is still unknown. Four PD patients presented FoG in the concurrent use of deep brain stimulation (DBS) and levodopa which was improved through discontinuation of either DBS or levodopa.

Parkinson’s disease (PD) is a progressive neurodegenerative disorder of central nervous system which affects dopaminergic neurons, mostly in the Substantia Nigra.1 Freezing of gate (FoG) is an abnormal and common gait pattern in PD and it is defined as a short and sudden episode of inability to initiate or continue walking despite the intention, especially in turning.2 Freezing is most commonly relieved by dopaminergic medication known as “off” FoG and conversely “on” state is a FoG resistant to dopaminergic medication.2 Another medical strategy that can improve FoG is deep brain stimulation (DBS) of the subthalamic nucleus (STN).3 In this paper, we intend to report the combined effect of levodopa and STN-DBS which led to FoG in four patients.

2 | CASE PRESENTATIONS

Herein, we present 4 patients with PD that they all underwent STN-DBS surgery under local anesthesia after obtaining the consent form. These patients were all referred to Shohada Tajrish University Hospital which is a referral center for DBS. This study was approved by ethical committee of Shahid Beheshti University of Medical Science.
2.1 | Patient 1

A 54-year-old, right-handed man presented with bradykinesia at age of 39, and PD was diagnosed for him at this age. By the time, the disease progressed and he experienced severe wearing off which could not be controlled by medical management, and he did not have dyskinesia, dystonia, or FoG. Patients' surgery was done in another country when he was 44. After 4 years, he started to present freezing of gait and arm rising dystonia on the left hand which became more severe over times. Two years ago, he came to our DBS clinic to consult for spinal stimulation surgery. He was on levodopa/carbidopa 100/25 mg, four times a day, propranolol 20 mg/day, and diazepam 2 mg/day. The patient stated that his FoG and dystonia occur 30 minutes after taking levodopa and 30 minutes before the next dose. Therefore, levodopa/carbidopa has been reduced to 100mg/day and his FoG improved completely without changing DBS parameters (Table 1), and then, amantadine was added to his medications and his dystonia improved as well.

2.2 | Patient 2

A 57-year-old right-handed woman was diagnosed with PD, akinetic rigid type, at age 47, and at age of 54, STN-DBS surgery was carried out for her because of severe wearing off and dyskinesia, while she was on levodopa/carbidopa 200/50mg, 8 times a day, pramipexole 0.18 mg, 2 times a day, and amantadine once daily. Because of severe dyskinesia, levodopa was decreased gradually to levodopa/carbidopa 100/25 mg, five times a day, and in addition to her dyskinesia, FoG improved dramatically. During 2 years of follow-up, she could not decrease levodopa/carbidopa anymore and she currently has mild freezing of gait after using levodopa. DBS parameters are available in Table 1.

2.3 | Patient 3

A 65-year-old right-handed woman with a 10-year history of PD referred to our DBS clinic due to FoG and backward arms movement during walking, and DBS surgery was done at age 61 because of severe refractory tremor. She did not have dyskinesia and FoG before surgery. She was on levodopa/benserazide 200/50 mg, 5 times a day. Medication was reduced to levodopa/benserazide 250 mg, ¼ tab, 4 times per day. In response to medication reduction, patient has shown relieving in FoG and sudden episodes of movement breakdown compared with simultaneous use of DBS and high dosage of dopaminergic medication. DBS parameters are available in Table 1.

2.4 | Patient 4

A 62-year-old right-handed woman with history of akinetic rigid PD since age of 49 was referred to our clinic because of severe FoG and dyskinesia. STN-DBS electrodes were implanted when she was at the age of 59, when she did not have freezing of gait. The patient was wheelchair bound due to FoG and was taking Levodopa/carbidopa 125 mg, 10 times per day. Because of dyskinesia, levodopa/carbidopa was tapered without DBS adjustment. Three weeks later, she came to our clinic when she withdrew her medication and could walk with cane, and did not have FoG and dyskinesia. DBS parameters are available in Table 1. After 2 years of follow-up, she still remained drug-free without episodes of FoG.

3 | DISCUSSION

DBS is among the treatment strategies considered for poorly controlled patients with Parkinson’s disease, but it has demonstrated controversial outcomes specifically in the improvement of FoG. STN is shown to be a possibly proper target for DBS in PD. Although some studies have noted an improvement in the FoG subsequent to STN-DBS, some others have reported worsening of FoG or emergence of new cases. Malposition of the electrodes (eg, anteromedial placement of electrode in STN) and improper (possibly high) voltage and frequency of stimulation may be responsible for newly emerged FoG and progression of the disease may lead to a decline in FoG improvement during years after DBS. In a case report by Mei et al., a patient with new-onset FoG, subsequent to the combined utilization of levodopa and DBS, has been reported for the first time. Similar to their report, here we present 4 cases of PD undergone STN-DBS who showed new-onset FoG whenever they took levodopa and the DBS device was on. FoG of these patients was induced by neither dopamine medication nor DBS alone, and it resolved after discontinuation of levodopa.

It has been suggested that disturbances in dopamine-related neural pathways are among the most possible underlying causes of Parkinson’s disease signs and symptoms including FoG. Intake of levodopa would increase the level of dopamine and improves the patients’ status. Roshan Cools and Mark D’Esposito have discussed that dopamine possesses an inverted-U-shaped performance meaning that through the range of doses/concentration, the maximal effect would be achieved at the middle of the range, whereas
| Data/Patients | Patient 1 | Patient 2 | Patient 3 | Patient 4 |
|---------------|-----------|-----------|-----------|-----------|
| **Baseline**  |           |           |           |           |
| EF:           | Case(+), 3(+) | 3(+), 2(-) | Case(+), 2 and 3(-) | Case(+), 0 and 2(-) |
| Amp:          | 3.7, 3.7   | 2.9, 1.7  | 3.0, 1.7  | 1.8, 1.8  |
| PW:           | 60, 60     | 60, 60    | 60, 60    | 60, 60    |
| Rate:         | 85, 85     | 90, 90    | 90, 90    | 120,120   |
| Complaint:    | freezing of gait, hand dystonia | freezing of gait, dyskinesia | hands tremor | hands tremor |
| Medication:   | levodopa/carbidopa(100/25) 1/2 four times a day | levodopa/carbidopa(100/10) 3/4 six times a day | levodopa/benzeriside(100/25) 1/2 four times a day | levodopa/benzeriside(100/25) 1/2 four times a day |
| **3 months**  |           |           |           |           |
| EF:           | case(+), 3(+) | 3(+), 2(-) | case(+), 2 and 3(-) | case(+), 0 and 2(-) |
| Amp:          | 3.9, 4.2   | 2.2, 0.7  | 3.0, 1.7  | 1.8, 1.8  |
| PW:           | 60, 60     | 60, 60    | 60, 60    | 60, 60    |
| Rate:         | 85, 85     | 90, 90    | 90, 90    | 120,120   |
| Complaint:    | speech difficulty | wearing off | hands tremor | bradykinesia, speech difficulty |
| Medication:   | levodopa/carbidopa(100/25) 1/2 four times a day | levodopa/carbidopa(100/10) 3/4 six times a day | levodopa/benzeriside(100/25) 1/2 four times a day | none |
| **12 months** |           |           |           |           |
| EF:           | case(+), 3(+) | 3(+), 2(-) | case(+), 2 and 3(-) | case(+), 0 and 2(-) |
| Amp:          | 4.1, 4.4   | 2.7, 1.2  | 3.6, 1.7  | 1.8, 1.8  |
| PW:           | 60, 60     | 60, 60    | 70,70     | 60,60     |
| Rate:         | 85, 85     | 90, 90    | 140,140   | 110,110   |
| Complaint:    | bradykinesia | wearing off | hands tremor | bradykinesia, legs tremor |
| Medication:   | levodopa/carbidopa(100/25) 1/2 four times a day | levodopa/carbidopa(100/10) 3/4 six times a day | levodopa/benzeriside(100/25) 1/2 four times a day | none |
| **24 months** |           |           |           |           |
| EF:           | case(+), 3(+) | 3(+), 2(-) | case(+), 2 and 3(-) | case(+), 0 and 2(-) |
| Amp:          | 4.7,4.6    | 2.3, 1.0  | 5.2,2.7   | 1.5,1.5   |
| PW:           | 60, 60     | 80,80     | 90,90     | 60,60     |
| Rate:         | 95, 95     | 90, 90    | 155,155   | 110,110   |
| Complaint:    | hands tremor | freezing, dyskinesia | hands tremor | speech difficulty |
| Medication:   | levodopa/carbidopa(100/25) 1/2 four times a day | levodopa/carbidopa(100/10) 5/5 times a day | levodopa/benzeriside(100/25) 1/2 four times a day | none |
extrema of this range demonstrate significantly lower performance (eg, FoG). Interestingly, DBS would lead to changes in the concentration of dopamine in a frequency-dependent manner in a similar way so that within a range of frequencies, the highest concentration is achieved via the frequencies in the middle of the range while lower and higher frequencies lead to lower concentration of dopamine. These two latter statements are consistent with each other, and it would be possible that the response of FoG to DBS varies depending on the frequency of the DBS and concentration of dopamine. As all four patients developed FoG subsequent to the combination of dopamine and DBS and neither of levodopa and DBS were capable of inducing FoG alone, it can be hypothesized that because of the dopamine medication which would increase the basal levels of dopamine and further DBS utilization which would induce the release of dopamine more than before, the level of dopamine would pass the concentration threshold that respected optimal function is expected and would reach to the concentration threshold which the function of dopamine is not beneficial and effective (the higher extremum of inverted-U-shaped performance) (Figure 1). In this case, although the combination of dopamine intake and DBS increases the level of dopamine, the proper decrease of FoG would not be observed. Three of these reported patients also developed dystonia in simultaneous utilization of levodopa and DBS. It has been suggested that dystonia and FoG may have similar underlying mechanisms and our evidences may strengthen this hypothesis.

4 | CONCLUSION

Here, we have reported that new-onset FoG can occur in concurrent use of levodopa and DBS in PD patients. It has been suggested that this observation may be due to high concentrations of dopamine in certain sites of brain subsequent to concurrent use of levodopa and DBS and an inverted-U-shaped function of dopamine.

ACKNOWLEDGMENTS

Published with written consent of the patient.

CONFLICTS OF INTEREST

All authors declare no conflicts of interest.

AUTHOR CONTRIBUTIONS

Reza Jalili khoshnood performed the surgery. Mehri Salari involved in visiting patients and stimulation adjustment. Sepand Tehrani Fateh and Zahra Aminzade wrote the manuscript. Sepand Tehrani Fateh involved in schematic illustration. Mehri Salari and Sepand Tehrani Fateh edited the study. Mehri Salari involved in supervision.

DATA AVAILABILITY STATEMENT

All data will be available through a request from the corresponding author.

ORCID

Mehri Salari https://orcid.org/0000-0002-1675-681X
Zahra Aminzade https://orcid.org/0000-0002-2018-3436
Sepand Tehrani Fateh https://orcid.org/0000-0003-2842-0480

REFERENCES

1. Poewe W, Seppi K, Tanner CM, et al. Parkinson disease. Nat Rev Dis Primers. 2017;3(1):1-21.
2. Weiss D, Schoellmann A, Fox MD, et al. Freezing of gait: understanding the complexity of an enigmatic phenomenon. Brain. 2020;143(1):14-30.
3. Fasano A, Aquino CC, Krauss JK, Honey CR, Bloem BR. Axial disability and deep brain stimulation in patients with Parkinson disease. *Nat Rev Neurol*. 2015;11(2):98.

4. Schlenstedt C, Shalash A, Muthuraman M, Falk D, Witt K, Deuschl G. Effect of high-frequency subthalamic neurostimulation on gait and freezing of gait in Parkinson’s disease: a systematic review and meta-analysis. *Eur J Neurol*. 2017;24(1):18-26.

5. Xie T, Kang UJ, Warnke P. Effect of stimulation frequency on immediate freezing of gait in newly activated STN DBS in Parkinson’s disease. *J Neurol Neurosurg Psychiatry*. 2012;83(10):1015-1017.

6. Umemura A, Oka Y, Okita K, Toyoda T, Matsukawa N, Yamada K. Predictive factors affecting early deterioration of axial symptoms after subthalamic nucleus stimulation in Parkinson’s disease. *Parkinsonism Relat Disord*. 2010;16(9):582-584.

7. Tommasi G, Lopiano L, Zibetti M, et al. Freezing and hypokinesia of gait induced by stimulation of the subthalamic region. *J Neurol Sci*. 2007;258(1–2):99-103.

8. Mei S, Li J, Middlebrooks EH, et al. New onset on-medication freezing of gait after STN-DBS in Parkinson’s disease. *Front Neurol*. 2019;10:659.

9. Cools R, D’Esposito M. Inverted-U–shaped dopamine actions on human working memory and cognitive control. *Biol Psychiatry*. 2011;69(12):e113-e125.

10. Xiao G, Song Y, Zhang YU, et al. Dopamine and striatal neuron firing respond to frequency-dependent dbs detected by microelectrode arrays in the rat model of Parkinson’s disease. *Biosensors*. 2020;10(10):136.

11. Shimo Y, Hatano T, Sakurai M, Sekimoto S, Marisdina S, Hattori N. Freezing of gait in Parkinson’s disease may share the mechanisms of dystonia. *Neurol Sci*. 2020;41(5):1285-1286.

**How to cite this article:** Salari M, Aminzade Z, Jalili khoshnood R, Tehrani Fateh S. Case series: New-onset freezing of gait in combined use of deep brain stimulation and Levodopa. *Clin Case Rep*. 2021;9:e04695. [https://doi.org/10.1002/ccr3.4695](https://doi.org/10.1002/ccr3.4695)